15
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Invited Review: APOE at the interface of inflammation, neurodegeneration and pathological protein spread in Alzheimer's disease

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Despite more than a century of research, the aetiology of sporadic Alzheimer's disease ( AD) remains unclear and finding disease modifying treatments for AD presents one of the biggest medical challenges of our time. AD pathology is characterized by deposits of aggregated amyloid beta (Aβ) in amyloid plaques and aggregated tau in neurofibrillary tangles. These aggregates begin in distinct brain regions and spread throughout the brain in stereotypical patterns. Neurodegeneration, comprising loss of synapses and neurons, occurs in brain regions with high tangle pathology, and an inflammatory response of glial cells appears in brain regions with pathological aggregates. Inheriting an apolipoprotein E ε4 ( APOE4 ) allele strongly increases the risk of developing AD for reasons that are not yet entirely clear. Substantial amounts of evidence support a role for APOE in modulating the aggregation and clearance of Aβ, and data have been accumulating recently implicating APOE4 in exacerbating neurodegeneration, tau pathology and inflammation. We hypothesize that APOE4 influences all the pathological hallmarks of AD and may sit at the interface between neurodegeneration, inflammation and the spread of pathologies through the brain. Here, we conducted a systematic search of the literature and review evidence supporting a role for APOE4 in neurodegeneration and inflammation. While there is no direct evidence yet for APOE4 influencing the spread of pathology, we postulate that this may be found in future based on the literature reviewed here. In conclusion, this review highlights the importance of understanding the role of APOE in multiple important pathological mechanisms in AD.

          Related collections

          Most cited references124

          • Record: found
          • Abstract: found
          • Article: not found

          Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families.

          The apolipoprotein E type 4 allele (APOE-epsilon 4) is genetically associated with the common late onset familial and sporadic forms of Alzheimer's disease (AD). Risk for AD increased from 20% to 90% and mean age at onset decreased from 84 to 68 years with increasing number of APOE-epsilon 4 alleles in 42 families with late onset AD. Thus APOE-epsilon 4 gene dose is a major risk factor for late onset AD and, in these families, homozygosity for APOE-epsilon 4 was virtually sufficient to cause AD by age 80.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy

            APOE4 is the strongest genetic risk factor for late-onset Alzheimer disease. ApoE4 increases brain amyloid-β pathology relative to other ApoE isoforms. However, whether APOE independently influences tau pathology, the other major proteinopathy of Alzheimer disease and other tauopathies, or tau-mediated neurodegeneration, is not clear. By generating P301S tau transgenic mice on either a human ApoE knock-in (KI) or ApoE knockout (KO) background, here we show that P301S/E4 mice have significantly higher tau levels in the brain and a greater extent of somatodendritic tau redistribution by three months of age compared with P301S/E2, P301S/E3, and P301S/EKO mice. By nine months of age, P301S mice with different ApoE genotypes display distinct phosphorylated tau protein (p-tau) staining patterns. P301S/E4 mice develop markedly more brain atrophy and neuroinflammation than P301S/E2 and P301S/E3 mice, whereas P301S/EKO mice are largely protected from these changes. In vitro, E4-expressing microglia exhibit higher innate immune reactivity after lipopolysaccharide treatment. Co-culturing P301S tau-expressing neurons with E4-expressing mixed glia results in a significantly higher level of tumour-necrosis factor-α (TNF-α) secretion and markedly reduced neuronal viability compared with neuron/E2 and neuron/E3 co-cultures. Neurons co-cultured with EKO glia showed the greatest viability with the lowest level of secreted TNF-α. Treatment of P301S neurons with recombinant ApoE (E2, E3, E4) also leads to some neuronal damage and death compared with the absence of ApoE, with ApoE4 exacerbating the effect. In individuals with a sporadic primary tauopathy, the presence of an ε4 allele is associated with more severe regional neurodegeneration. In individuals who are positive for amyloid-β pathology with symptomatic Alzheimer disease who usually have tau pathology, ε4-carriers demonstrate greater rates of disease progression. Our results demonstrate that ApoE affects tau pathogenesis, neuroinflammation, and tau-mediated neurodegeneration independently of amyloid-β pathology. ApoE4 exerts a ‘toxic’ gain of function whereas the absence of ApoE is protective.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease.

              To assess the relationship between dementia, neuronal loss, and neuropathological findings in Alzheimer's disease (AD), we counted the number of neurons, senile plaques, and neurofibrillary tangles in a high-order association cortex. We studied the superior temporal sulcus of 34 individuals with AD and 17 nondemented control subjects, using statistically unbiased, stereological counting techniques. The number of superior temporal sulcus neurons in nondemented control subjects was stable across the sixth to ninth decades. In AD, more than 50% of the neurons were lost. Both neuronal loss and neurofibrillary tangles increased in parallel with the duration and severity of illness, but the amount of neuronal loss exceeded by manyfold the amount of neurofibrillary tangles accumulated. In contrast to the correlation between neurofibrillary tangles and neuronal loss, the number of senile plaques and the percentage of the superior temporal sulcus that was covered by Abeta (amyloid burden) were not related to neuronal loss, number of neurofibrillary tangles, or duration of disease. Neither the amount nor the rate of neuronal loss in the superior temporal sulcus in AD correlated with apolipoprotein E genotype. These data suggest that neuronal loss in association areas such as the superior temporal sulcus contributes directly to cognitive impairment in AD.
                Bookmark

                Author and article information

                Contributors
                Tara.spires-jones@ed.ac.uk
                Journal
                Neuropathol Appl Neurobiol
                Neuropathol. Appl. Neurobiol
                10.1111/(ISSN)1365-2990
                NAN
                Neuropathology and Applied Neurobiology
                John Wiley and Sons Inc. (Hoboken )
                0305-1846
                1365-2990
                28 November 2018
                June 2019
                : 45
                : 4 ( doiID: 10.1111/nan.2019.45.issue-4 )
                : 327-346
                Affiliations
                [ 1 ] UK Dementia Research Institute and Centre for Discovery Brain Sciences The University of Edinburgh Edinburgh UK
                [ 2 ] Massachusetts General Hospital and Harvard Medical School Charlestown MA USA
                Author notes
                [*] [* ]Correspondence: Tara Spires‐Jones, UK Dementia Research Institute and Centre for Discovery Brain Sciences, The University of Edinburgh, 1 George Square, Edinburgh EH8 9JX, UK. Tel: +44(0)1316511895; E‐mail: Tara.spires-jones@ 123456ed.ac.uk
                [†]

                Equal contributions.

                Author information
                http://orcid.org/0000-0002-2660-5943
                http://orcid.org/0000-0003-2422-0633
                http://orcid.org/0000-0003-2530-0598
                Article
                NAN12529
                10.1111/nan.12529
                6563457
                30394574
                1af16634-1371-459d-9a11-931ed02eef29
                © 2018 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd on behalf of British Neuropathological Society.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                : 11 October 2018
                : 27 October 2018
                Page count
                Figures: 7, Tables: 0, Pages: 20, Words: 12107
                Funding
                Funded by: UK Dementia Research Institute
                Funded by: Medical Research Council
                Funded by: Alzheimer's Research UK
                Funded by: Wellcome Trust
                Funded by: Alzheimer's Society
                Categories
                Invited Review
                Invited Review
                Custom metadata
                2.0
                nan12529
                June 2019
                Converter:WILEY_ML3GV2_TO_NLMPMC version:5.6.4 mode:remove_FC converted:13.06.2019

                Neurosciences
                alzheimer's disease,apoe,apolipoprotein e,glia,inflammation,neurodegeneration,tau
                Neurosciences
                alzheimer's disease, apoe, apolipoprotein e, glia, inflammation, neurodegeneration, tau

                Comments

                Comment on this article